When they isolated and studied BPC 157 peptide, they found something unexpected: this peptides protective mechanisms werent limited to the digestive tract
The plasma concentrations of ferulic acid were also almost constant between 2 and 14 h after intake of Pycnogenol and the steady state concentrations after multiple doses appeared high compared to the single dose ( FIGURE 2 FIGURE 3 In this pioneer pharmacokinetic study with Pycnogenol , ten unknown compounds were found in plasma samples in addition to the identified ones ( , were assigned a molecular structure ( In a study with osteoarthritis patients (see section 5.2 Distribution into blood cells), steady state serum concentrations were determined after intake of 200 mg Pycnogenol per day (Table 2)
In macrophages, the most pronounced reduction was around 20% for IL-1 (from above 300 to less than 250 pg/mL) and approximately 45% in TNF- levels (from around 1800 to 1000 pg/mL) [30]
Composition & Format Active components per vial: TB-500 10mg + BPC-157 10mg + GHK-Cu 50mg Total fill: 70 mg blue copper lyophilized powder Kit size: 10 vials/kit, tray-packed for export Consistent cap colors and batch coding to support visual stock control Key Features for Wholesale Buyers High-purity peptide blend manufactured in a China-based factory environment Blue copper appearance from GHK-Cu for easy identification in storage trays Peptide kits prepared for OEM / private-label projects on request Suitable for distributors needing regular, repeatable batch supply Packaging & Ordering Default configuration: 10 vials/kit in protective plastic trays Pouches, labels and outer cartons are packed for international transit and warehouse handling For current stock status, wholesale pricing and freight options, please contact us directly for a formal quotation Order processing and dispatch updates are generally available within 3 business days after payment confirmation Storage & Handling Store vials sealed at 28 C , protected from light and moisture Avoid repeated freezethaw cycles
In Kennedy's February remarks about his aim to allow compounding of more than a dozen peptides in the U.S., he suggested that peptides made within the country would be safer than ones acquired abroad
